The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations
      Google Scholar   
Citation:
Blood vol 130 (Suppl 1) 2580
Meeting Instance:
ASH 2017
Year:
2017
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
3367  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Novartis Pharma  
Grants:
U10CA180821, U10CA180882, U10CA31946, U10CA180791, U10CA180820, U10CA180888, U24CA196171, U10CA180863, (CCSRI) 704970;  
Corr. Author:
 
Authors:
                                                       
Networks:
CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-OH007   
Study
CALGB-10603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: